Még nem toboroz
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
NCT07791732· 3. fázis· Daiichi Sankyo· Forrás
Még nem toboroz
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· 2. fázis· Agomab Spain S.L.U.· Forrás
Még nem toboroz
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· 3. fázis· Novo Nordisk A/S· Forrás
Még nem toboroz
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Még nem toboroz
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· 3. fázis· Almirall, S.A.· Forrás
Toboroz
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
NCT07890454· 3. fázis· Sanofi· Forrás
Toboroz
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
NCT07843472· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· 3. fázis· Janssen Cilag International· Forrás
Toboroz
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
2026-525489-23-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
NCT07583446· 2/3. fázis· Seismic Pharmaceuticals Operations LLC· Forrás
Még nem toboroz
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
2026-526419-13-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic
Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
2025-524793-42-00· 2. fázis· Janssen Cilag International· Forrás
Még nem toboroz
Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.
2025-524606-15-00· 3. fázis· Tecnimede-Sociedade Tecnico-Medicinal S.A.· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· 1/2. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
NCT07720375· 2. fázis· UCB Biopharma SRL· Forrás
Toboroz
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510· 3. fázis· Dianthus Therapeutics· Forrás
Toboroz
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· 3. fázis· PureTech· Forrás
Toboroz
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
2025-524404-29-00· 2. fázis· Eli Lilly & Co.· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881· 3. fázis· Rapport Therapeutics Inc.· Forrás
Toboroz
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
NCT07333066· 3. fázis· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Forrás
Toboroz
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· 3. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288· 2. fázis· AbbVie· Forrás
Toboroz
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· 3. fázis· Sanofi· Forrás
Toboroz
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder.
2025-522026-13-00· 2. fázis· Bioprojet Pharma· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187· 2/3. fázis· AbbVie· Forrás
Toboroz
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
NCT06908304· 3. fázis· Maia Biotechnology· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of rhinitis/rhinoconjunctivitis in patients allergic to house
dust mites.
2023-508548-23-00· 3. fázis· Inmunotek S.L.· Forrás
Toboroz
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT07168434· 3. fázis· Biocodex· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417· 3. fázis· Alfasigma S.p.A.· Forrás
Contact: Henedina Antunes, MD
Toboroz
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· 3. fázis· Kura Oncology, Inc.· Forrás
Toboroz
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
2024-518586-10-00· 2/3. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-Δ tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain
2024-520287-34-01· 2. fázis· Ferraz Lynce Especialidades Farmaceuticas S.A.· Forrás
Toboroz
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)
2024-519521-37-01· 2/3. fázis· Corxel Pharmaceuticals Co. Ltd.· Forrás
Showing 50 of 144.